Friday, May 9, 2025
Home Tags DYAI

Tag: DYAI

2020 Watch List

Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines...

Editor / Curator -
Dyadic, Biotech Stock Review
2020 Watch List

Dyadic (DYAI) Price Target $12.

Editor / Curator -
Biotech News

Update: Biotech 5 Pack. 5 Biotech Stocks, we Expected to Double...

Editor / Curator -
Dyadic
Biotech News

Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce...

Editor / Curator -
Immunomedics, Biotech Stock Review
All News

Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in...

Editor / Curator -
biogen, biotech stock review
Biotech News

Biotech’s Turning Up…

Editor / Curator -
Dyadic, Biotech Stock Review
Biotech News

Dyadic (DYAI) Highlights.

Editor / Curator -
Dyadic, Biotech Stock Review
Biotech News

Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

Editor / Curator -
Dyadic
Biotech News

Investor Presentation Slides From Dyadic (DYA) $6.40.

Editor / Curator -
biotech stock review, dyadic
All News

Must Watch Video: Dyadic’s (DYAI) Matthew Jones.

Editor / Curator -
12Page 1 of 2

Latest article

Zomedica Corp (ZOMDF) $0.05

Uncategorized Editor / Curator -
Company Overview Background Zomedica Corp., incorporated in 2013 under the Business Corporations Act (Alberta), is...

Gold prices plunge in biggest one-day drop in years. Is the record rally over?...

All News Editor / Curator -
Easing anxieties over Trump’s tariff policies and the Fed chair’s fate spark gold’s worst daily decline since 2021 Gold...

Gold Price Sets New Intraday Record Above $3,500 (WSJ)

All News Editor / Curator -
Gold hit another record Tuesday, then faded a bit in afternoon trading. The most actively traded futures contracts surged...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.